StockWatch
·

Vikran Engineering Ltd Q1 FY27 Results

VIKRANQ1 FY27 Results
Filing
Result:Weak· Market: CrashedMargin squeeze

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValuevs Q4 FY26
Revenue141.59 Cr78.1%
Total Income151.78 Cr76.8%
Expenditure146.35 Cr74.6%
PBT5.43 Cr93.0%
Net Profit3.99 Cr92.9%
OPM7.97%6.27pp
NPM2.63%5.93pp
EPS0.1593.1%
View full financials

Infrastructure core revenue fell 11% YoY with PAT down 29.4% and OPM nearly halved (14.2%→8.0%), a clear below-par quarter on both growth and margin.

VIKRAN · Q1 FY27 · THE VERDICT

Strong Standalone Growth Masked by Consolidation—NOPL Execution Risk Remains Acute

Consolidated revenue fell 11%, but standalone surged 28%. The gap reflects first-time NOPL consolidation and JJM receivable provisions. The real question: can NOPL deliver ₹1,500 Cr revenue over nine months without slipping?

18 Aug 2026 · 6 min read
Consolidated Revenue

₹141.6 Cr

-11% YoY

Standalone Revenue

₹204 Cr

+28% YoY

Consolidated PAT

₹4.0 Cr

-29% YoY

Standalone PAT

₹17.5 Cr

+210% YoY

EBITDA Margin (Consol)

8.0%

vs 14-15% target

Order Book

₹6,496 Cr

62% solar EPC

The consolidated result is a clean miss: revenue −11%, PAT −29%, EBITDA margin collapsing to 8% versus the 14–15% target. But drill into standalone—which excludes the newly consolidated NOPL Solar—and the picture inverts. Standalone revenue +28%, PAT +210%. The gap isn't a business deterioration; it's an accounting event. NOPL's first-time full consolidation created a ₹62 Cr revenue elimination (work now booked as asset/capex instead), and a ₹6.5 Cr JJM receivables provision temporarily gutted margins. Peel that back, and the underlying EPC business is executing well. The real risk isn't the near-term miss—it's whether NOPL can deliver ₹1,500 Cr revenue over the next nine months without slipping.

Why the consolidated result leans so hard on two adjustments

NOPL Solar became Vikran's 100% subsidiary in Q1 (post-restructuring). Under consolidation accounting, the ₹62 Cr of NOPL EPC work Vikran executed in Q1 is now eliminated as inter-company and reclassified as capex. Revenue recognition happens post-commissioning. The ₹6.5 Cr JJM provision reflects slow recovery on Jal Jeevan Mission projects (₹120 Cr debtor outstanding, extended to FY28). Together, these two items explain most of the consolidated revenue miss versus guidance and all of the margin collapse. Management expects both to normalize: JJM provisions reverse as receivables come in (₹23 Cr recovered in Q1; pace accelerating per management), and NOPL revenue kicks in as commissioned MW ramp in H2.

Revenue, ₹ Cr
-93.9216.03125.97235.92204Standalone Revenue-62NOPL inter-co eliminate142Consolidated Revenue
NOPL consolidation creates a ₹62 Cr optical decline. Revenue recognition shifts post-commissioning.
Management's key claims versus what the numbers support

28% standalone revenue growth, 212% PAT growth

Standalone ₹204 Cr +28.2% YoY, PAT ₹17.5 Cr +209.9% YoY confirmed.

Supported

Strong EBITDA margin resilience in EPC business

Standalone EBITDA 13.7% within 14–15% target. Consolidated 8% due to ₹6.5 Cr JJM provision and NOPL overhead. Margin resilience on core EPC; consolidated depressed by temporary factors.

Partially supported

NOPL 45 MW commissioned, on track for 12-month execution plan

45 MW operational, 15 MW ready, 240 MW in advanced stage. ₹1,500 Cr revenue planned H2. Execution track record emerging but aggressive timeline.

Supported

JJM receivables recovery by FY28; WC stable at ₹120 Cr debtor level

₹120 Cr JJM debtor outstanding; ₹23 Cr recovered in Q1. Scheme extended to FY28 (versus prior implied recovery). Recovery pace slower than guidance implied.

Supported but timeline extended

No stress on EPC margins or working capital; no equity dilution needed

Standalone EPC margins 14–17% holding firm. WC strategy: fix at ₹120 Cr, only invest what client pays. NOPL funded 75–25 debt-equity via IREDA and others. No immediate equity dilution flagged.

Supported

What changed on this call

Three shifts from prior quarters: (1) NOPL is now fully consolidated (100% subsidiary after restructuring). Inter-company eliminations create the ₹62 Cr revenue gap—temporary until post-commissioning. (2) Order book scaled to ₹6,496 Cr (up from ~₹3.5k prior year), with solar now 62% of the mix (₹3,518 Cr NOPL EPC). Strategic pivot toward higher-upside asset-play credentials materialized. (3) JJM recovery path extended to FY28, slower than prior implied guidance. ₹29 Cr disputed receivable also remains unresolved in court (strong case per CFO, but timeline uncertain). Despite these headwinds, management reaffirmed FY27 guidance (₹2,200–2,500 Cr revenue, 14–15% EBITDA margin)—no raise, which signals execution conservatism given the size of NOPL.

The bull-bear ledger
  • Order book scaled to ₹6.5k Cr (18+ month visibility)

  • Standalone revenue +28%, PAT +210% (core EPC strong)

  • NOPL 45 MW operational in 2.5 months (execution proof)

  • Consolidated revenue −11%, PAT −29% (guidance miss)

  • EBITDA margin 8% versus 14–15% target (−600 bps shortfall)

  • NOPL 62% of order book (concentration risk)

  • JJM ₹120 Cr debtor (receivables quality weak, extended to FY28)

  • ₹29 Cr disputed receivable unresolved (timing uncertain)

  • Guidance reaffirmed, not raised (conservative, credible)

  • IREDA ₹3,100 Cr financing expected Q1 (unlocks NOPL capex)

Risks, ranked by holder concern

What can derail the story

NOPL execution slippage (969 MW in 12 months)

High

62% of order book hinges on a single aggressive timeline. Any delay >2–3 months cascades to FY27 revenue miss and jeopardizes ₹2,200–2,500 Cr guidance. Financing, supply chain, and monsoon risk all material.

JJM receivables recovery slower than expected

High

₹120 Cr debtor, extended to FY28. If recovery remains stuck, working capital stress could force equity raise despite 'no dilution' guidance. Also masks true earnings quality (provisions mask recurring weakness).

Margin compression persists into H2 FY27

High

Consolidated 8% versus 14–15% target isn't just temporary. If JJM provisions don't reverse fast enough and NOPL capex overhead drags, blended margin could stay depressed through FY27. Credibility of 14–15% target declines.

Financing closure delays (IREDA final sanction)

Medium

IREDA sanction pending committee meeting. Disbursement expected Q1 FY27. Delay >1–2 months would push NOPL capex timeline and cascade to H2 revenue ramp delays.

₹29 Cr disputed receivable court verdict timing

Low

Strong case per management but unresolved. Timing uncertain. If lost, ₹29 Cr write-off. If won, one-time ₹29 Cr gain (positive surprise, but not transformative given scale).

How the street is positioned—and why it rejected the print

The stock price tells its own story: ₹61.09 as of 2026-08-18, down 48.4% from its all-time high of ₹118.4. It's trading below its 20-day, 50-day, and 200-day moving averages (SMA20 ₹69.87, SMA50 ₹71.66, SMA200 ₹79.51). RSI at 19.7 signals technical oversold, yet volume is increasing—a sign of institutional capitulation rather than accumulation. The result-day reaction was swift: −10.21% on day 1, −15.51% by day 3. The market rejected the standalone growth narrative and focused on the consolidated miss. Ownership data confirms institutional hesitation: FII holdings fell to 1.27% (QoQ −0.16pp), DII reduced to 5.74% (−1.09pp). Promoter stake steady at 56.27%, with no insider selling near the highs (latest bulk deals in June 2026 traded around ₹76). The 48% drawdown from ATH has likely created a risk/reward bottleneck: the stock is deeply undervalued if NOPL executes, but offers little margin of safety if H2 ramps disappoint.

What to watch next—the roadmap to the ₹2,400 Cr question
  • 1 · IREDA financial closure (Q1 FY27)

    Management expects final sanction and disbursement this quarter. This unlocks ₹3,900–4,200 Cr NOPL capex in earnest. Delay >1–2 months cascades to H2 revenue delays.

  • 2 · NOPL revenue ramp visibility (Q2 FY27 onwards)

    Target ₹100 Cr September, bulk of ₹1,500 Cr in H2 remaining quarters. First major disclosure of unit/MW delivery pace and revenue conversion will validate 12-month execution thesis. Any Q2 miss signals broader timeline risk.

  • 3 · JJM receivables recovery acceleration

    ₹23 Cr recovered in Q1; ₹10+ Cr more in last 30 days per management. If pace sustains or improves, JJM provisions reverse in H2, and consolidated margin rebounds toward 12–13%. If stalls, working capital stress persists.

  • 4 · FY27 run-rate guidance versus H1 actuals

    If H1 (Apr–Sep) posts ~₹500–600 Cr revenue (low due to seasonality), H2 must deliver ₹1,600–1,900 Cr to hit ₹2,100–2,500 Cr full-year. This is the conversation that will define FY27 credibility.

  • 5 · Standalone margin stability into H2

    If standalone EPC continues to deliver 13.7–15% EBITDA despite market competition, confidence in the 14–15% blended target (ex-temporary JJM drag) strengthens. Margin deterioration here would be a red flag.

The honest read

This is a story of execution dependency masquerading as accounting noise. The consolidated miss (−11% revenue, −29% PAT) is real but partly optical: NOPL consolidation accounts for ₹62 Cr of the decline, and JJM provisions depress EBITDA by 6+ points. Strip those, and the underlying EPC business is executing well (+28% standalone growth, 13.7% margins). But the market is right to be skeptical. NOPL is now 62% of the order book, a 969 MW 12-month timeline is aggressive, and receivables pressure (₹120 Cr JJM debtor, ₹29 Cr dispute) remains unresolved.

Management is candid and not defensive. They've reaffirmed guidance rather than raised it—a sign of execution realism. NOPL's 45 MW in 2.5 months gives early credibility. But the 48% drawdown from ATH and institutional trimming (FII −0.16pp, DII −1.09pp QoQ) reflect a market that is not confident this becomes a step-change story. It's a steady-execution bet, priced for skepticism.

The verdict: Hold. The stock is cheap on NOPL upside, but the near-term (9–12 months) remains binary. Watch FY27 revenue run-rate and H2 NOPL ramp closely. If IREDA closes Q1 and September sees ₹100+ Cr NOPL revenue delivery, the narrative re-rates. If either slips, expect re-rating lower. The single number to track from here is FY27 consolidated revenue run-rate (targeting ₹2,200–2,500 Cr). Achieve that, and the ₹61 valuation becomes attractive. Miss it by >10%, and the receivables and concentration risks become structural.

Informational and educational content only. Not investment advice.